Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

532 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients.
Huebner H, Häberle L, Müller V, Schrader I, Lorenz R, Forstbauer H, Fink V, Schochter F, Bekes I, Mahner S, Jückstock J, Nabieva N, Schneeweiss A, Tesch H, Brucker SY, Blohmer JU, Fehm TN, Heinrich G, Rezai M, Beckmann MW, Fasching PA, Janni W, Rack B. Huebner H, et al. Among authors: fehm tn. Cancers (Basel). 2022 Mar 28;14(7):1721. doi: 10.3390/cancers14071721. Cancers (Basel). 2022. PMID: 35406491 Free PMC article.
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial.
Riethdorf S, Müller V, Zhang L, Rau T, Loibl S, Komor M, Roller M, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Eidtmann H, Untch M, von Minckwitz G, Pantel K. Riethdorf S, et al. Clin Cancer Res. 2010 May 1;16(9):2634-45. doi: 10.1158/1078-0432.CCR-09-2042. Epub 2010 Apr 20. Clin Cancer Res. 2010. PMID: 20406831 Clinical Trial.
HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.
Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, Lattrich C, Löhberg CR, Solomayer E, Rack B, Riethdorf S, Klein C, Schindlbeck C, Brocker K, Kasimir-Bauer S, Wallwiener D, Pantel K. Fehm T, et al. Breast Cancer Res Treat. 2010 Nov;124(2):403-12. doi: 10.1007/s10549-010-1163-x. Epub 2010 Sep 22. Breast Cancer Res Treat. 2010. PMID: 20859679 Clinical Trial.
Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis.
Janni W, Vogl FD, Wiedswang G, Synnestvedt M, Fehm T, Jückstock J, Borgen E, Rack B, Braun S, Sommer H, Solomayer E, Pantel K, Nesland J, Friese K, Naume B. Janni W, et al. Clin Cancer Res. 2011 May 1;17(9):2967-76. doi: 10.1158/1078-0432.CCR-10-2515. Epub 2011 Mar 17. Clin Cancer Res. 2011. PMID: 21415211
Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.
Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, Fischer D, Sommer HL, Conrad B, Ortmann O, Fehm T, Rezai M, Mehta K, Loibl S; German Breast Group Investigators. Gerber B, et al. J Clin Oncol. 2011 Jun 10;29(17):2334-41. doi: 10.1200/JCO.2010.32.5704. Epub 2011 May 2. J Clin Oncol. 2011. PMID: 21537042 Clinical Trial.
532 results